** Shares of drugmaker EyePoint Pharmaceuticals EYPT.O rise ~11% to $8.47
** EYPT says its drug, Duravyu, met the main goal in mid-stage trial for the treatment of diabetic macular edema, a condition where fluid builds up in the central part of the retina due to damaged blood vessels
** The main goal was to evaluate if the drug could reduce the frequency of injections needed to treat the condition compared to the standard treatment, aflibercept
** 2.7 mg dose of Duravyu helped 73% of patients avoid extra injections, compared to 50% of patients treated with aflibercept - EYPT
** Co plans to initiate a late-stage non-inferiority trial for the drug by the end of 2025
** EYPT fell ~67% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.